Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02961218
Recruitment Status : Completed
First Posted : November 10, 2016
Last Update Posted : May 20, 2020
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
To determine the effect of canakinumab versus placebo on daily pain experienced by sickle cell anemia patients (Reduction of average daily pain VAS over the period of Week 8 to 12 as compared to baseline levels).

Condition or disease Intervention/treatment Phase
Sickle Cell Anemia Drug: Ilaris, Canakinumab Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multiple-dose, Subject- and Investigator-blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
Actual Study Start Date : April 5, 2017
Actual Primary Completion Date : June 27, 2019
Actual Study Completion Date : April 27, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia
Drug Information available for: Canakinumab

Arm Intervention/treatment
Placebo Comparator: Placebo
Matching placebo administered subcutaneously
Drug: Placebo
Monthly doses of placebo to match the administered dose of canakinumab s.c.

Experimental: Ilaris, Canakinumab
Randomized drug administration for 24 weeks duration (6 drug administrations each 28 days apart) followed by an additional 24-week open label phase (6 drug administrations each 28 days apart).
Drug: Ilaris, Canakinumab
Monthly doses of 300 mg canakinumab subcutaneously (s.c)




Primary Outcome Measures :
  1. Reduction of average daily pain [ Time Frame: Week 8 to 12 ]
    Primary endpoint is the reduction of average daily pain measured with a visual analog scale over the period of Week 8 to 12 as compared to baseline levels


Secondary Outcome Measures :
  1. Reduction of average daily pain over 24 weeks [ Time Frame: Baseline, 24 weeks ]
    Reduction of average daily pain measured with a visual analog scale over 4-week intervals up to Week 24 as compared to baseline levels

  2. The effect of canakinumab versus placebo on sickle cell anemia related days missed from school or work [ Time Frame: 56 weeks ]
    The number of days absent from school or work due to pain as recorded daily in an e-diary

  3. Measurement of pharmacokinetics of canakinumab in sickle cell anemia patients, which will be presented as descriptive summary statistics of pharmacokinetic concentrations. [ Time Frame: 48 weeks ]
    serial serum PK determination, 9 samples over 48 weeks, in patients with sickle cell anemia

  4. Week 12 versus baseline of white blood cell count [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory markers of inflammation

  5. Week 12 versus baseline of absolute counts of blood neutrophils [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory markers of inflammation

  6. Week 12 versus baseline of absolute counts of blood monocytes [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory markers of inflammation

  7. Week 12 versus baseline of serum hs-CRP [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory markers of inflammation

  8. Week 12 versus baseline of Hemoglobin concentration [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory and functional markers of hemolysis

  9. Week 12 versus baseline of reticulocyte count [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory and functional markers of hemolysis

  10. Week 12 versus baseline of Haptoglobin [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory and functional markers of hemolysis

  11. Week 12 versus baseline of LDH [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory and functional markers of hemolysis

  12. Week 12 versus baseline of total bilirubin [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory and functional markers of hemolysis

  13. Week 12 versus baseline of oxygen percent saturation (SAO2) [ Time Frame: Baseline, 12 weeks ]
    The effect of canakinumab versus placebo measured with laboratory and functional markers of hemolysis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects ages 8-20 years of age (both inclusive) diagnosed with sickle cell anemia (HbSS) or sickle beta0 thalassemia (documented by family studies, or analysis of either hemoglobin or DNA).
  • Patient's written informed consent from those ≥18 years of age must be obtained before any assessment is performed. Parent or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for patients < 18 years of age.
  • Detectable baseline of background or episodic pain measured by daily e-diary over 1 to 2 weeks during screening period as defined below: Average daily pain score ≥ 1 cm without analgesic use over a period of at least 7 days and/or, At least one episode of pain requiring analgesic use during a period of up to 14 days.
  • History of ≥2 vaso-occlusive pain episodes in the past year, as defined as pain with no other, non-sickle cell identifiable cause that requires analgesia and interferes with the patient's normal daily routine.

Exclusion Criteria:

  • History of known hypersensitivity to canakinumab.
  • Ongoing or treatment with the past 3 months with red blood cell transfusion therapy, or have evidence of iron overload requiring chelation therapy.
  • Transcranial Doppler ultrasound in the past year or at screening in patients with an accessible transtemporal window, demonstrating velocity in middle or anterior cerebral or internal carotid artery ≥200 cm/sec.
  • Administration of any other blood products within 3 weeks of screening visit.

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02961218


Locations
Layout table for location information
United States, Georgia
Novartis Investigative Site
Atlanta, Georgia, United States, 30329
Novartis Investigative Site
Augusta, Georgia, United States, 30912
United States, North Carolina
Novartis Investigative Site
Greenville, North Carolina, United States, 27834
Canada, Ontario
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 1X8
Germany
Novartis Investigative Site
Hamburg, Germany, 20246
Israel
Novartis Investigative Site
Afula, Israel, 1834111
South Africa
Novartis Investigative Site
Johannesburg, Guateng, South Africa, 2193
Turkey
Novartis Investigative Site
Adana, Turkey, 01330
Novartis Investigative Site
Ankara, Turkey, 06100
Novartis Investigative Site
Mersin, Turkey, 33343
United Kingdom
Novartis Investigative Site
London, United Kingdom, E1 1BB
Novartis Investigative Site
London, United Kingdom, NW1 2BU
Novartis Investigative Site
London, United Kingdom, SE1 7EH
Novartis Investigative Site
London, United Kingdom, SE5 9RS
Novartis Investigative Site
Staffordshire, United Kingdom, WS11 5XY
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02961218    
Other Study ID Numbers: CACZ885X2206
First Posted: November 10, 2016    Key Record Dates
Last Update Posted: May 20, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Sickle cell disease
hemoglobinopathy
pediatric
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Anemia, Sickle Cell
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn